Skip to content

Effect of serteraline in depressed aggressive patients

Description and comparison of autonomous nervous system function in aggressive depressed patients before and after serteralin treatment by the measurement of related biomarkers

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201411122999N4
Enrollment
50
Registered
2015-07-10
Start date
2015-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression. Depression NOS

Interventions

At first, the patients are scored by "Beck" 2nd edition questionnaire and "Structured Clinical Interview-DSM-IV (SCID) for severity of depression, and also by "State-Trait Anger Expression Inventory-2
Treatment - Drugs

Sponsors

Tabriz University Of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to 39 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Depression should be confirmed by a psychologist throughout a structured interview based on DSM-IV criteria; Patient should be at 1st episode of disease, with no history of anti-depression treatment (medical or non-medical); Presence of aggressive behaviors confirmed by history or medical examination; Patient prefers taking more efficient drug, no matter how expensive; Iranian nationality; Age between 20 to 40 years old; Agreement for participating in study through signing testimonial form Exclusion criteria: History of any psychological disease, except for depression; Present history of any drug affecting CNS/PNS; History of any of these conditions: Amyloidosis, Acute porphyria, Cardiovascular/Respiratory/Endocrine/Neurologic disease, Alcohol/drug abuse, Malabsortion, Multiple sclerosis, ALS; Pre-menstural syndrome for female; Presence of genetical susceptibility to above mentioned conditions

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Depression intensity. Timepoint: 1.5. Method of measurement: Beck Questionnaire, 2nd edition.;Anger status. Timepoint: 1.5. Method of measurement: STAXI Questionnaire, 2nd edition.;Heart rate variability. Timepoint: 1.5. Method of measurement: Biofeedback system.;Respiratory Rate. Timepoint: 1.5. Method of measurement: Biofeedback system.;Heart rate. Timepoint: 1.5. Method of measurement: Biofeedback system.;Skin Temprature. Timepoint: 1.5. Method of measurement: Biofeedback system.;Blood Pressure. Timepoint: 1.5. Method of measurement: Biofeedback system.;Valsalva Ratio. Timepoint: 1.5. Method of measurement: Biofeedback system.;Expiratory:Inspiratory ratio. Timepoint: 1.5. Method of measurement: Biofeedback system.;Skin conductivity level. Timepoint: 1.5. Method of measurement: Biofeedback system.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArezoo Mehrara

Tabriz University Of Medical Science

arezoo.mehrara@gmail.com+98 41 3386 4208

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026